BH3 profiling - Measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions

Cancer Letters

Volumn 332, Issue 2, 2013, Pages 202-205

  Del Gaizo Moore, Victoria ^a   Letai, Anthony ^b  

^a ELON UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; BCL 2; BH3; BH3 only; Mitochondria

Indexed keywords

BH3 PROTEIN; PROTEIN BCL 2;

APOPTOSIS; CARCINOGENESIS; CELL ASSAY; CELL FATE; CELL STIMULATION; GENE OVEREXPRESSION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 84876070821     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.12.021     Document Type: Review

References (34)

1. Bakhshi A., Jensen J.P., Goldman P., Wright J.J., McBride O.W., Epstein A.L., Korsmeyer S.J. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 1985, 41:899-906.
2. Cleary M.L., Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc. Natl. Acad. Sci. USA 1985, 82:7439-7443.
3. Tsujimoto Y., Gorham J., Cossman J., Jaffe E., Croce C.M. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 1985, 229:1390-1393.
4. Brunelle J.K., Letai A. Control of mitochondrial apoptosis by the Bcl-2 family. J. Cell Sci. 2009, 122:437-441.
5. Green D.R., Evan GI G.I. A matter of life and death. Cancer Cell 2002, 1:19-30.
6. Cory D., Adams J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2002, 2:647-656.
7. Liang H., Fesik S.W. Three-dimensional structures of proteins involved in programmed cell death. J. Mol. Biol. 1997, 274:291-302.
8. Rutledge S.E., Chin J.W., Schepartz A. A view to a kill: ligands for Bcl-2 family proteins. Curr. Opin. Chem. Biol. 2002, 6:479-485.
9. Petros A.M., Olejniczak E.T., Fesik S.W. Structural biology of the Bcl-2 family of proteins. Biochim. Biophys. Acta 2004, 1644:83-94.
10. Sattler M., Liang H., Nettesheim D., Meadows R.P., Harlan J.E., Eberstadt M., Yoon H.S., Shuker S.B., Chang B.S., Minn A.J., Thompson C.B., Fresik S.W. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997, 275:983-986.
11. Lindsten T., Ross A.J., King A., Zong W.X., Rathmell J.C., Shiels H.A., Ulrich E., Waymire K.G., Mahar P., Frauwirth K., Chen Y., Wei M., Eng V.M., Adelman D.M., Simon M.C., Ma A., Golden J.A., Evan G., Korsmeyer S.J., MacGregor G.R., Thompson C.B. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol. Cell 2000, 6:1389-1399.
12. Wei M.C., Zong W.X., Cheng E.H., Lindsten T., Panoutsakopoulou V., Ross A.J., Roth K.A., MacGregor G.R., Thompson C.B., Korsmeyer S.J. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001, 292:727-730.
13. Cheng E.H., Wei M.C., A H.-Y., Weiler S., Flavell R.A., Mak T.W., Lindsten T., Korsmeyer S.J. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol. Cell 2001, 8:705-711.
14. Oltvai Z.N., Milliman C.L., Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993, 74:609-619.
15. Certo M., Del Gaizo Moore V., Nishino M., Wei G., Korsmeyer S.J., Armstrong S.A., Letai A. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006, 9:351-365.
16. Del Gaizo Moore V., Brown J.R., Certo M., Love T.M., Novina C.D., Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J. Clin. Invest. 2007, 117:112-121.
17. Del Gaizo Moore V., Schlis K.D., Sallan S.E., Armstrong S.A., Letai A. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood 2008, 111:2300-2309.
18. Deng J., Carlson N., Takeyama K., Dal Cin P., Shipp M.A., Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007, 12:171-185.
19. Letai A., Bassik M.C., Walensky L.D., Sorcinelli M.D., Weiler S.S., Koresmeyer S.J. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002, 2:183-192.
20. Cartron P.F., Gallenne T., Bougras G., Gautier F., Manero F., Vusio P., Meflah K., Vallette F.M., Juin P. The first alpha helix of Bax plays a necessary role in its ligand-induced activation by the BH3-only proteins Bid and PUMA. Mol. Cell 2004, 16:807-818.
21. Kuwana T., Bouchier-Hayes L., Chipuk J.E., Bonzon C., Sullivan B.A., Green D.R., Newmeyer D.D. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol. Cell 2005, 17:525-535.
22. Zong W.X., Lindsten T., Ross A.J., MacGregor G.R., Thompson C.B. BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev. 2001, 15:1481-1486.
23. Gavathiotis E., Suzuki M., Davis M.L., Pitter K., Bird G.H., Katz S.G., Tu H., Kim H., Cheng E., Tjandra N., Walensky L.D. BAX activation is initiated at a novel interaction site. Nature 2008, 455:1076-1081.
24. Albeck J.G., Burke J.M., Aldridge B.B., Zhang M., Lauffenburger D.A., Sorger P.K. Quantitative analysis of pathways controlling extrinsic apoptosis in single cells. Mol. Cell 2008, 30:11-25.
25. Opferman J.T., Letai A., Beard C., Sorcinelli M.D., Ong C.C., Korsmeyer S.J. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003, 426:671-676.
26. Chen L., Willis S.A., Wei A., Smith B.J., Fletcher J.I., Hinds M.G., Colman P.M., Day C.L., Adams J.M., Huang D.C.S. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell 2005, 17:393-403.
27. Evan G.I., Wyllie A.H., Gilbert C.S., Littlewood T.D., Land H., Brooks M., Waters C.M., Penn L.Z., Hancock D.C. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992, 69:119-128.
28. Letai A., Beard C., Sorcinelli M., Korsmeyer S.J. Anti-apoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell 2004, 6:241-249.
29. Brunelle J.K., Ryan J., Yecies D., Opferman J.T., Letai A. MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts. J. Cell Biol. 2009, 187:429-442.
30. Del Gaizo Moore V., Letai A. Rational design of therapeutics targeting the BCL-2 family: are some cancer cells primed for death but waiting for a final push?. Adv. Exp. Med. Biol. 2008, 615:159-175.
31. Letai A.G. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat. Rev. Cancer 2008, 8:21-132.
32. Schimmer A.D., Hedley D.W., Chow S., Pham N.A., Chakrabartty A., Bouchard D., Mak T.W., Trus M.R., Minden M.D. The BH3 domain of BAD fused to the Antennapedia peptide induces apoptosis via its alpha helical structure and independent of Bcl-2. Cell Death Differ. 2001, 8:725-733.
33. Ryan J.A., Brunelle J.K., Letai A. Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes. Proc. Natl. Acad. Sci. USA 2010, 107:12895-12900.
34. Yamaguchi R., Andreyev A., Murphy A.N., Perkins G.A., Ellisman M.H., Newmeyer D.D. Mitochondria frozen with trehalose retain a number of biological functions and preserve outer membrane integrity. Cell Death Differ. 2007, 14:616-624.